- 24/7 Wall St.•15 hours ago
Despite solid tailwinds, some companies are still holding back the rally. Some of them are hitting lows and creating huge shareholder losses.
- Business Wire•2 days agoSHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Amicus Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Amicus Therapeutics, Inc. concerning possible violations of federal securities laws.
- PR Newswire•2 days agoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amicus Therapeutics, Inc. - FOLD
NEW YORK, Dec. 1, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Amicus Therapeutics, Inc. ("Amicus" or the "Company") (FOLD). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 9980. On this news, Amicus stock fell $1.81, or 21.75%, to close at $6.51 on November 29, 2016. The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation.
FOLD : Summary for Amicus Therapeutics, Inc. - Yahoo Finance
Amicus Therapeutics, Inc. (FOLD)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
|Bid||5.63 x 300|
|Ask||6.68 x 1000|
|Day's Range||5.78 - 6.10|
|52 Week Range||4.98 - 10.54|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-4.09|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|